VEDOLIZUMAB SHOWS BETTER TREATMENT OUTCOMES THAN INFLIXIMAB FOR PATIENTS WITH ULCERATIVE COLITIS REFRACTORY TO TREATMENT WITH ADALIMUMAB: A PROPENSITY SCORE ANALYSIS OF UK IBD BIORESOURCE OUTCOMES
Christina Kapizioni 1
Rofaida Desoki 1
Miles Parkes 1
Tim Raine 1
1 Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Topic
IBD, Immunology, Paediatrics
Session
IBD: Clinical trials I
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]